8 results
The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children aged from 2 to less than 7 years old.
The primary objective of the study is to test the effectiveness of bumetanide across the whole spectrum of sensory processing disorders within ASD, ADHD and/or epilepsy. We also want to determine which subgroups (high/low IQ, comorbidities or not)…
The primary objective of the proposed study is to investigate whether bumetanide therapy indeed reduces autistic symptomatology. Important secondary goals of this project are to determine whether bumetanide will improve specific behavioral,…
To assess changes in inflammatory cytokine release of monocytes and neutrophils stimulated with MSU crystals, isolated from patients with chronic coronary artery disease after colchicine 0.5mg daily during one month, compared to no colchicine…
Primary: Part 1 • To determine the RP2D of avapritinib in patients with ISM for use in Part 2 and Part 3 of the study.Part 2 • To determine main change in ISM-SAF TSS from baseline to C7D1, compared to placebo. Part 3 • To assess the long-term…
The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children and adolescents aged from 7 to less…
The main objective of this study is to determine the effect of colchicine on the progression of moderate AS in asymptomatic patients.
Primary Objectives: • To study the causal role of inflammation in affecting food-related effort-based decision making in brain and behaviour in overweight and obese participants by employing a placebo-controlled intervention design with the anti-…